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Abstract
Background: This single center, double-blinded, cross-over, placebo controlled clinical trial investigated the effect
of oral α-cyclodextrin (α-CD), a soluble dietary fiber, on blood lipid and lipoprotein levels in healthy human subjects.
α-CD, a cyclical polymer containing 6 glucose subunits, is currently sold as an over the counter food supplement
and is also a common additive in many foods. α-CD forms a hydrophobic central cavity that binds lipids and has
been shown in animal studies and in previous clinical trials to alter plasma lipid levels.
Methods: We screened for healthy subjects, males and females, between ages 18 to 75. Out of total 103 subjects
interviewed, 75 subjects completed the study. Qualified individuals in each gender group were randomized into
two groups in terms of which treatment arm they received first (placebo vs. α-CD, receiving 6 grams P.O. a day, for
12–14 weeks with a 7 day wash out between arms). The primary outcome variable, plasma total cholesterol, as well
as other tests related to lipids and lipoprotein and glucose metabolism, were measured at baseline and at the end
of each arm of the study.
Results: α-CD was well tolerated; no serious adverse events related to α-CD were observed. Approximately 8 %
of the subjects on α-CD complained of minor gastrointestinal symptoms versus 3 % on placebo (p = 0.2). Small-LDL
particle number decreased 10 % (p < 0.045) for subjects on α-CD versus placebo. Fasting plasma glucose (1.6 %,
p < 0.05) and Insulin resistance index (11 %, p < 0.04) were also decreased when on α-CD versus placebo.
Conclusion: α-CD treatment appears to be safe and well tolerated in healthy individuals and showed a modest
reduction in small LDL particles, and an improvement in glucose related parameters.
Trial registration: NCT01131299
Keywords: α-cyclodextrin, TC, Total cholesterol, TG, Triglycerides, LIRI, Lipoprotein Insulin Resistance Index, LDL-C,
Low density lipoprotein cholesterol, HDL-C, High density lipoprotein cholesterol, BAS, Bile acid sequestrants
Background
Despite numerous therapeutic advances, CVD remains
the leading cause of morbidity and mortality in devel-
oped countries [1]. The major modifiable risk factors for
CVD include elevated low density lipoprotein cholesterol
(LDL-C), decreased high density lipoprotein cholesterol
(HDL-C), diabetes, cigarette smoking, inactivity, obesity
and a poor diet, which is often low in soluble fiber and
high in saturated and trans fats [2]. Although statins are
the most effective therapeutic agents for reducing CVD
risk, they only reduce cardiovascular events by approxi-
mately 30 % [3]. Soluble dietary fibers and bile acid
sequestrants are two other currently used agents for
lowering serum lipids [4]. Bile acid sequestrants (BAS)
are among the oldest lipid-altering drugs and have been
known for decades to also improve glucose control and
to reduce CVD risk [5]. Both of these agents, however,
have relatively poor compliance because of the large
amount of agent that is needed to achieve a lipid lowering
effect, poor palatability and gastrointestinal discomfort [6].
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Soluble dietary fibers, which exist in a normal diet and
are commonly used food additives, are also known to
reduce blood cholesterol levels [7]. A recent meta-
analysis, however, concluded that most soluble fibers re-
duce total cholesterol (TC) by relatively small amounts,
approximately 1.6 mg/dL per gram of soluble fiber [8].
For a normal-weight subject following a recommended
diet of 2000 kcal/day containing 30 % fat, this amounts
to only about a 4.6 % reduction in total cholesterol (TC)
levels. Another meta-analysis of 8 controlled interven-
tion trials reported only a 4 % reduction in TC levels in
hypercholesterolemic subjects that consumed as much
as 10 g psyllium per day [9].
α-CD is a soluble fiber derived from corn and is used
as an ingredient in many foods, such as bread rolls,
crackers, juices, chewing gum and reduced fat spreads
[10]. Based on safety data, α-CD has been granted Gen-
erally Recognized As Safe (GRAS) status by the FDA
[11, 12]. It is commonly added to food as a fiber supple-
ment but is also used as a stabilizer of flavors, colors,
vitamins and fatty acids and for improving the mouth-
feel of beverages [11]. It is also sold for human con-
sumption as a dietary food supplement and is distributed
by many health food stores. Unlike most other soluble
fibers, which are long linear or branched polymers, α-
CD is a cyclic polymer and forms a toroidal-like structure.
It contains 6 glucose molecules, which form a central
hydrophobic cavity with high affinity for lipids, such as
cholesterol and other fats [11]. One possible advantage of
α-CD over other soluble fibers or over BAS in lowering
plasma lipids is that less agent may be required to com-
plex fat in the diet, because of its relative high affinity for
lipid. One gram of α-CD has been shown to bind as much
as nine grams of dietary fat [13]. It is also tasteless and
anecdotal reports from subjects taking α-CD as a dietary
food supplement suggest that it is well tolerated and
causes minimal gastrointestinal discomfort.
Our previous animal studies, in mice, demonstrated
that the addition of oral α-CD to regular chow diet im-
proved the lipid profile by lowering pro-atherogenic li-
poproteins and trans-fatty acids and by decreasing the
ratio of saturated and trans-fatty acids to polyunsatur-
ated fatty acids [14]. In this study, low-density lipopro-
tein receptor knockout mice were fed a “Western diet”
(21 % milk fat) with or without 2.1 % of α-CD (10 % of
dietary fat content) for 14 weeks. At sacrifice, there was
no difference in body weight; however, significant de-
creases were observed in plasma cholesterol (−15.3 %),
free cholesterol (−20 %), cholesteryl esters (−14 %), and
phospholipids (−17.5 %) levels in mice treated with α-
CD compared with control mice. Furthermore, α-CD
improved the blood fatty acid profile, reducing the satu-
rated fatty acids (−4.5 %) and trans-isomers (−11 %),
while increasing unsaturated fatty acids (2.5 %) [15].
Results from this study are consistent with other animal
studies, showing the possible utility of α-CD as a dietary
supplement for decreasing serum lipids [12, 16, 17].
There have only been, however, a limited number of
human studies on α-CD [13, 18, 19]. In one study con-
ducted by Grunberger and colleagues in obese (BMI >
30) type II diabetic patients, treatment with α-CD (6 g a
day) for 3 months led to a reduction or maintenance of
body weight, an increase in insulin sensitivity as a result
of increased levels of adiponectin, and a lowering of
plasma triglyceride and LDL cholesterol, with no apparent
side effects [13]. A second study conducted by Buckley
and colleagues also on diabetic patients aimed to under-
stand the effects of α-CD on acute glucose and insulin
response to a standard carbohydrate meal (50 g of carbo-
hydrate in white rice) containing 0 to 10 g of α-CD.
They observed significantly reduced post-prandial
plasma glucose levels without any increase insulin re-
sponse for subjects ingesting α-CD. It was also ob-
served that α-CD was associated with an increased
incidence of minor gastrointestinal complaints (stom-
ach ache, nausea, bloating), but this was primarily
observed in subjects on a low fat diet [19].
In the present study, we examined in a randomized
cross-over placebo-control design the effect of oral α-
CD in a relatively healthy control population without
diabetes and or obesity to determine if α-CD supple-
mentation could have broader health benefits in the
general population. The primary outcome variable was
plasma total cholesterol but other measures related to
lipid and glucose control were also assessed.
Methods
Subject and experimental participants
We screened 103 subjects, males and females, be-
tween the ages of 18–75. 75 subjects completed the
study, and were randomized into two groups first re-
ceiving either placebo or α-CD followed by the other
treatment (Fig. 1).
The inclusion and exclusion criteria were designed to
recruit a relatively healthy population and subjects with
diabetes were specifically excluded (Table 1). The study
was approved by the NHLBI IRB under protocol # 10-
H-0088 and FDA IND # 108017. All participants signed
a consent form. Out of the 103 subjects enrolled in the
study, 75 completed the study. Fifteen subjects were ex-
cluded for laboratory abnormalities at baseline and 13
subjects were withdrawn prior to completion of the
study for non-compliance with the drug intake schedule.
Study design
This was a single center, double-blinded, cross-over,
placebo-controlled trial (Fig. 1). The individuals in
each gender group, who qualified for the study, were
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randomized into two groups in terms of which treat-
ment arm they received first (placebo or α-CD). There
were a total of 3 visits for this study. Eligible subjects
received placebo pills or α-CD (6 grams P.O. a day;
two 1 gram tablets per meal) for 12–14 weeks, with a
one week of wash out period between arms (Fig. 1).
To control for diet and exercise changes, a seven day
food diary was obtained prior to the initiation of each
study arm and were analyzed, using Nutrition Data
Systems for Research, versions 2010–2013 (Mineapo-
lis, MN). In addition, a member of the research team
periodically contacted the subjects to monitor compli-
ance. A short physical activity assessment and gastro-
intestinal symptoms were recorded during each visit.
α-CD was manufactured by Wacker Biochem (Adrian,
MI), under GMP guidelines. The pills containing
1000 mg of α-CD plus Croscarmelose Sodium, Stearic
Acid, Magnesium Stearate, Silicon Dioxide as excipients
were purchased from ArtJen Complexus Holdings Corp.
Identical looking placebo pills were also purchased
from ArtJen Complexus Holdings Corp. Placebo pills
contained 300 mg of Calcium from the Di-Calcium
phosphate, 160 mg of cellulose per tablet and same ex-
cipients as α-CD pills.
Sample analysis
Approximately 40 mL of fasting blood samples were col-
lected at each visit and used to perform the following
routine laboratory tests: Sodium (Na), Potassium (K),
Chloride (Cl), Bicarbonate, Creatinine, Glucose, Urea ni-
trogen (BUN), Albumin, Calcium, Alkaline Phosphatase,
ALT/GPT, AST/GOT, Total Bilirubin, Total Protein,
Lipid Panel, Lipoprotein NMR profile, Thyroid Panel,
hs-CRP, vitamin A, vitamin E, carotene, HbA1C, and in-
sulin. These tests were performed in the Department of
Laboratory Medicine in the NIH Clinical Center (CC).
Statistical analysis
It was estimated that a minimum sample size of approxi-
mately 62 subjects was needed to detect an 8 mg/dl
change in total plasma cholesterol levels between the
placebo and α −CD treatment periods, with an 80 %
power, by using the normal approximation to a one-
sample (paired), two-sided t-test at an alpha = 0.05. A
standard deviation of 20 mg/dl was assumed for the
paired differences in plasma cholesterol levels between
the two treatment periods. An expected attrition rate
was set to 30 %, therefore, the power calculations pre-
dicted that a total sample size of n = 70 was needed for
the study.
Descriptive statistics were calculated for all variables.
All response variables were assessed for conformance to
the normal distribution and transformed as needed to
Fig. 1 Experimental design of the study
Table 1 Inclusion and exclusion criteria of the study
Inclusion criteria
• Males and females, ages of 18–75.
• Understands and provides written, informed consent.
Exclusion Criteria
• Pregnancy or breastfeeding.
• BMI < 18.5
• Weight (change > 10 % over in the past 3 months).
• Low-fat (<20 %) diet.
• Less than 3 meals/snacks per day
• Use of medications for at least six weeks: soluble fiber supplements,
BAS, plant sterol supplements, long term antibiotics, anticoagulants,
anticonvulsants, antiarrhythmics, cyclosporine, mycophenolate,
synthroid, vitamin A, E and K or drugs taken with a meal.
• Chronic diarrhea, gastric bypass or lapband procedures, ostomies,
bowel motility problems, or conditions that could affect intestinal fat
absorption.
• New or multiple medications.
• Type I or type II diabetes.
• Use of α-CD in any of its commercial form.
• Condition or disorder that may affect the outcome of the study or
the safety of the volunteer.
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meet the assumptions of normal distribution and homo-
geneity between periods. Statistically significant differ-
ences in response variables for subjects on placebo
versus α-CD treatment arms were determined by two-
tailed paired t-test analysis. Chi-square analysis was
used to compare the frequency of side effects on pla-
cebo versus the α-CD treatment. HOMA index was
calculated as previously described [20]. All statistical
analysis were done with JMP by SAS Institute and
Graphpad Prism v. 6.0
Results
Baseline patient characteristics
A total of 103 subjects were screened and 89 subjects
who met the inclusion and exclusion criteria were en-
rolled into the study. 2 subjects were later excluded
during the study for non-compliance and 12 subjects
voluntarily withdrew after starting the study, leaving a
total of 75 subjects that completed the study (34 males
and 41 females). Of the 12 subjects that withdrew while
on the study, one subject withdrew before starting the
treatment, and 11 subjects withdrew while taking the
study medication; 8 were on the α-CD arm (4 because of
gastrointestinal symptoms), and 3 were on the placebo
arm (2 because of gastrointestinal symptoms; p =NS).
No other common cause for withdrawing from the study
was given.
Baseline characteristics for the subjects recruited for
the study are shown in Table 2. The mean age of the
participants were 34 ± 12 years and they had a mean
BMI of 25 ± 4 kg/m2. The subjects were mainly of white
(71.8 %); 12.6 % were of Asian/Pacific Islander descent
and 9.7 % were African Americans.
The healthy subjects were recruited from the Be-
thesda, MD area and generally presented with relatively
normal clinical laboratory test values, including those
related to serum lipids and lipoproteins (Table 3).
Diet and exercise levels
Seven days before each visit, a food diary and an exercise
log was recorded by each subject and reviewed during
the nutritional assessment part of each visit.
The average energy and micronutrients intake during
the study is displayed in Table 4. No seasonal change in
food composition was observed during the study. Over-
all, the mean dietary nutrient intakes at baseline were
also similar in crossover groups. No significant change
in exercise levels or food consumption were observed
during the study.
Safety and tolerability
Besides the main outcome parameters related to lipids, a
panel of general laboratory tests was also monitored to as-
sess the safety of α-CD treatment (Table 5). No significant
differences were observed for any of the safety tests for
when patients were on placebo versus α-CD, including
those related to fat malabsorption (Vitamin A, D, and E).
Overall, the α-CD treatment (6 grams a day) was rea-
sonably well tolerated. There were a total of 35 adverse
events (A.E.) and 2 serious adverse events (S.A.E.) as
listed in Table 6. The two serious adverse events were
considered to be unrelated to the treatment (emergency
appendectomy, while on placebo and enrollment in an-
other conflicting clinical trial). A side effect possibly re-
lated to the intake of α-CD was mild GI symptoms,
which were more frequent on the α-CD arm (8 %) ver-
sus the placebo arm (3 %), but this did not reach statis-
tical significance (p = 0.19). Four subjects, however,
discontinued the study while on α-CD because of GI
complaints. Two subjects discontinued the study be-
cause of GI complaints while on placebo (p = NS).
Changes in lipid parameters
The results related to the main lipid and lipoprotien out-
come parameters are shown in Table 7. No statistially
Table 2 Baseline anthropometric characteristics of subjects
recruited
Age (years) n %
18 − 21 2 1.9
22 − 30 51 49.5
31 − 40 25 24.3
41 − 50 10 9.7
51 − 60 10 9.7
61 − 65 3 2.9
≥66 2 1.9
Mean SD







Asian or Pacific Islander 13 12.6
Hispanic 2 1.9
American Indian or Alaskan 0 0.0
Unknown 4 3.9
Anthropomorphic measures Mean SD
BMI (Kg/m2) 25 3.9
Weight (Kg) 75 17
Systolic Blood Pressure (mmHg) 119 12
Diastolic Blood Pressure (mmHg) 73 10
(n = number of subjects; % = percentage of total subjects recruited)
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signficant differences were observed in total cholesterol
or the other commonly measured lipid and lipoprotein
test parmeters for when patients were on α-CD treat-
ment versus placebo. Similarly, there was no change in
the LDL particle number (LDL-p) as determined by
NMR analysis [21]. The size distribution of LDL subrac-
tions, however, were different on α-CD treatment versus
placebo. After 12–14 weeks on α-CD treatment, there
was a 10 % reduction (p < 0.045) in small LDL-p com-
pared to placebo (Table 7). In numerous studies, it has
been shown that small LDL is more proatherogenic than
larger LDL subfractions [22–24]. The mean age, BMI or
ethnic distribution did not statistically differ between the
responders with a reduction of small LDL-p on α-CD
and the non-responders.
Table 3 Lipid profiles and laboratory values of subjects in the
placebo and α-CD groups at baseline
Baseline values / reference range Mean SEM
Safety parameters
CRP HS (<3.0 mg/L) 1.4 0.2
AST (9–34 U/L) 19.9 0.1
ALT (6–41 U/L) 29.3 1.5
TSH (0.40 − 4.00 mcIU/mL) 1.6 0.1
Urea (8–22 mg/dL) 3.6 0.5
Creatinine (0.56 − 1.16 mg/dL) 0.8 0.1
Albumin (3.5 − 5.2 g/dL) 4.2 0.1
Alk Phosp (35–105 U/L) 57.8 1.9
Vitamin A (24–85 mcg/dL) 55.5 1.6
Vitamin D (18–78 pg/mL) 54.5 1.7
Vitamin E (5.0 − 19.0 mg/L) 10.9 0.5
RBC (3.93 − 5.22 M/uL) 4.7 0.1
WBC (3.98 − 10.04 K/uL) 5.4 0.1
Lipids and Lipoproteins
Cholesterol (<200 mg/dL) 169.0 4.1
Triglycerides (<150 mg/dL) 94.0 5.9
LDL-C (<100 mg/dL) 101.0 4.0
HDL-C (>40 mg/dL) 59.6 2.0
Glucose metabolism
Glucose (74–106 mg/dL) 86.4 0.8
Hgb A1C (4.0 − 6.0 %) 5.3 0.1
Insulin (2.6 − 24.9 mcU/mL) 6.6 0.5
LIRIa (%, by NMR) 1.4 0.1
HOMA IR index 1.4 0.1
aLipoprotein Insulin Resistance Index [25]
Table 4 Average Daily Dietary Intake
Nutrient/food group Mean SD
Energy (Kcal/d) 2214.6 623.4
Protein (% energy) 17.3 4.1
Fat (% energy) 33.6 5.5
Carbohydrate (% energy) 46.6 8
Alcohol (% energy) 2.7 3.2
Grain Servingsa 6.9 2
Fruit Servingsa 1.9 1.5
Vegetable Servingsa 3.7 1.6
Protein Servingsa 6.6 2.9
Dairy Servingsa 2.1 1.1
Macronutrient composition of diet consumed by subjects and monitored by
7 days food records as described in the methods section
aServings were normalized for 2000 kcals/d
Table 5 Changes in safety values of subjects after 12–14 weeks on
placebo or α-CD either measured by conventional biochemistry
methods or by NMR (mean ± SEM)
Safety parameters Placebo α-CD p
CRP HS (<3.0 mg/L) 2.1 ± 0.5 2.0 ± 0.4 0.8
AST (9–34 U/L) 20.6 ± 0.7 19.2 ± 1.1 0.1
ALT (6–41 U/L) 28.6 ± 1.4 26.9 ± 1.1 0.08
TSH (0.40 − 4.00 mcIU/mL) 1.9 ± 0.1 1.9 ± 0.1 0.7
Urea (8–22 mg/dL) 13.3 ± 0.5 12.9 ± 0.5 0.4
Creatinine (0.56 − 1.16 mg/dL) 0.8 ± 0.2 0.8 ± 0.2 0.8
Albumin (3.5 − 5.2 g/dL) 4.2 ± 0.1 4.2 ± 0.1 0.8
Alk Phosp (35–105 U/L) 57.5 ± 1.8 57.5 ± 1.7 0.9
Vitamin A (24–85 mcg/dL) 55.9 ± 1.6 55.4 ± 1.6 0.6
Vitamin D (18–78 pg/mL) 52.3 ± 1.6 53.9 ± 1.9 0.3
Vitamin E (5.0 − 19.0 mg/L) 10.8 ± 0.4 10.8 ± 0.3 0.9
RBC (3.93 − 5.22 M/uL) 4.6 ± 0.1 4.6 ± 0.1 0.4
WBC (3.98 − 10.04 K/uL) 5.5 ± 0.1 5.4 ± 0.1 0.4
Table 6 Adverse events observed during the study
Adverse Events Probably/possible related AE
A.E. (Total n = 35) n % Study arma
Expected AE 10 28.6 α-CD Placebo
Probably related AE 9 25.7 Abdominal Pain 1 1
Possibly related AE 2 5.7 Intestinal Gas 3 0
Unrelated 14 40.0 Nausea 1 0
Diarrhea 2 1
S.A.E (Total n = 2) n % Urinary Urgency 0 1
Expected SAE 0 0 Dyspepsia 2 0
Related SAE 0 0 Cramps 1 0
Unrelated 2 100 Increased frequency 1 0
A.E. and S.A.E. were classified as expected/unexpected. Unexpected A.E. or S.A.E.
were classified as related, probably, possible or unrelated to the treatment
aChi-square p value = 0.19
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Changes in glucose-related parameters
Because α-CD treatment has previously been shown to
improve glucose control in overweight patients [18], sev-
eral tests related to glucose metabolism were also moni-
tored (Table 8). Body weight, serum insulin, and HbA1C
were unchanged by the α-CD treatment in the relatively
healthy population examined in this study, but we did
observe a small reduction in fasting glucose (−1.6 %; p =
0.05) in subjects when on α-CD versus placebo. The
HOMA index did not show any difference but an
insulin-resistance index based on NMR analysis [25] also
showed a modest improvement (−11 %, p < 0.04) when
subjects were on α-CD versus placebo. The mean BMI
or ethnic distribution did not statistically differ between
the responders with a reduction of the insulin-resistance
index on α-CD and the non-responders, but the mean
age of the responders (38 years) was significantly greater
than the non-responders (31 years; p < 0.01).
Discussion
In the present study, we investigated the effect of α-CD
supplementation on plasma lipid and glucose-related
parameters in a relatively healthy population. In contrast,
most of the other prior studies on α-CD were done on
overweight patients or on patients with diabetes and or
obesity [13, 18]. Although it was reasonably well tolerated
and appeared to be safe, α-CD in this study only had
minor beneficial effects on serum lipids and glucose, with
unknown clinical significance.
The safety and tolerability of α-CD observed in this
study is consistent with previous clinical trials [18, 19].
α-CD is largely non-absorbable [26] and when fully
hydrolyzed produces glucose monomers and hence is
thought to be relatively safe and has been granted GRAS
status by the FDA. We did observe a non-significant in-
crease in mild GI complaints when subjects were on α-
CD compared to placebo, but 4 subjects did drop out of
the study while on α − CD because of GI complaints.
Although α-CD is non-absorbable, it can be hydrolyzed
by gut bacteria [11, 26] and is thus considered a fer-
mentable fiber, which could possibly account for the GI
side effects.
In terms of lipid lowering, we observed a 10 % reduc-
tion in small LDL-particle number when subjects were
on α-CD versus placebo, with no other changes in the lipid
and lipoprotein profile. Small LDL has been shown in many
studies to be particularly pro-atherogenic [22–24], presum-
ably because of its ability to better infiltrate the vessel wall
and it increased propensity for oxidation [27, 28]. Whether
the change observed in this study is clinically significant in
the absence of a total reduction in LDL-P or LDL-C is not
clear. In previous animal studies, α-CD supplementation
has been shown to reduce LDL-C [15], but the dose used
in these studies was much higher than what was used
in this clinical trial. In a prior clinical trial of α-CD on
serum lipids, which used doses similar to our study,
found a reduction in LDL-C of 11.9 ± 4.2 mg/dL after
3 months on the α-CD treatment, while the placebo
group showed a 8.5 ± 6.2 mg/dL (p < 0.01) increase, but
this only occurred in hypertriglyceridemic obese pa-
tients with BMIs > 30 kg/m2 [13]. In another small
study of overweight individuals with a mean BMI of
26.9 kg/m2 and a mean age of 43.3 years, α-CD (6
grams per day) given for one month lowered LDL-C by
approximately 6.7 % and a greater reduction was also
seen in individuals with higher baseline triglycerides
[18]. Because the subjects in the current study had a
relatively normal lipid and lipoprotein profile at base-
line, were younger (mean age of 34 years) than the pre-
vious studies and had a mean BMI of 25 kg/m2, this
may have limited the effect from the α-CD treatment.
Overall, these results suggest that α-CD may be more
effective in lipid lowering in a more dyslipidemic and
obese population, but this will have to be more defini-
tively established in larger clinical trials.
Supplementation with α-CD was also found in the
current study to cause a slight lowering of fasting plasma
glucose and to improve the NMR-based insulin-
resistance score [26]. Major changes, however, would
not be expected in glucose metabolism based on the fact
Table 7 Changes in Lipid, apolipoprotein and lipoprotein values of
subjects after 12–14 weeks on placebo or α-CD either measured by
conventional biochemistry methods or by NMR (mean ± SEM)
Lipids and Lipoproteins Placebo α-CD p
Cholesterol (<200 mg/dL) 180 ± 4 180 ± 4 0.82
Triglycerides (<150 mg/dL) 97 ± 6 100 ± 6 0.92
LDL-C (<100 mg/dL) 103 ± 3 103 ± 3 0.91
LDL-p (<1000 nmol/L) 1038 ± 47 1005 ± 45 0.16
sLDL-p (<1317 nmol/L) 405 ± 38 365 ± 35 0.04a
HDL-C (<40 mg/dL) 58 ± 2 60 ± 2 0.95
HDL-p (24–49 umol/L) 35 ± 1 35 ± 1 0.90
aLipoprotein Insulin Resistance Index [25]
Table 8 Changes in weight and glucose metabolism related
parameters of subjects after 12–14 weeks on placebo or α-CD
either measured by conventional biochemistry methods or by
NMR (mean ± SEM)
Glucose metabolism Placebo α-CD p
Weight (Kg) 74.8 ± 1.9 74.7 ± 2 0.99
Glucose (74–106 mg/dL) 88 ± 0.9 87 ± 0.7 0.05a
Insulin (2.6 − 24.9 mcU/mL) 7.1 ± 0.5 7.3 ± 0.6 0.56
Hgb A1C (4.0 − 6.0 %) 5.3 ± 0.4 5.3 ± 0.4 0.46
LIRIa (%, by NMR) 1.6 ± 0.1 1.4 ± 0.1 0.04a
HOMA IR index 1.6 ± 0.1 1.5 ± 0.1 0.15
aLipoprotein Insulin Resistance Index [25]
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that we designed our selection criteria to recruit only
healthy subjects and at baseline our subjects had a mean
fasting glucose of only 86 ± 1 mg/dL, with a relatively
low mean insulin of 6.6 ± 05 mcU/mL. In 2012, the
European Food Safety Authority (EFSA) issued a scien-
tific opinion approving the claim that the consumption
of at least 5 g of α-CD in 50 g of starch will reduce post-
prandial glycemic responses. The results from our study
suggest, however, that at a dose of 6 g/day α-CD would
have only a minimal effect in glucose control in non-
obese healthy individuals.
The original rationale for why α-CD supplementation
may lower serum lipids is that it would interfere with
cholesterol or triglyceride absorption [13] like what has
been described for other soluble fibers [5]. α-CD is
known in vitro to bind to various lipids [15] but whether
this process is relevant to fat absorption in vivo is not
known [29]. Recently, it has been recognized that α-CD
can be hydrolyzed and fermented by gut bacteria [30]
and hence can be considered a pre-biotic. Supplementa-
tion with α-CD could, therefore, possibly change the
composition of the gut flora in favorably ways that could
improve lipid metabolism and insulin sensitivity [31, 32].
A similar mechanism has been proposed for how BAS
and other soluble fibers may also improve lipid and glu-
cose related parameters [5]. In a recent unpublished ani-
mal study in apoE-KO mice, we found by 16S ribosomal
RNA sequencing that 1.5 % supplementation of α-CD
markedly changed the gut microbiome, which has been
shown modulate atherosclerosis [33, 34].
Conclusion
In summary, α-CD supplementation was safe and rea-
sonably well tolerated in a healthy population and had
some minor beneficial effects in reducing small LDL-
particle number and fasting glucose. Additional studies
are needed to understand the consequence of such
changes, the mechanism of action of α-CD and its ef-
fect on lipid lowering and glucose control in other pa-
tient populations.
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